The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
The European Commission approved Bristol Myers Squibb’s Opdivo combination therapy for urothelial cancer based on Phase III ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
Analyst Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...
Lung Cancer is a complex and devastating disease with over 200,000 new cases in 2024 alone. Small Cell Lung Cancer, or SCLC, is one of the most aggressive cancers out there, ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma ...
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin ...